Table 3 Two subgroup analyses of patients with thrombocytopenia and arthritis at onset
| Â | SLE patients with arthritis at onset | SLE patients with thrombocytopenia at onset | ||||
|---|---|---|---|---|---|---|
Flare group (N = 67) | Stable remission group(N = 42) | P value | Flare group (N = 19) | Stable remission group(N = 7) | P value | |
Age (Year), mean (SD) | 43(13) | 46(8) | 0.008 | 41(14) | 63(9) | 0.067 |
Gender (female/male) | 62/5 | 35/7 | 0.207 | 18/1 | 7/0 | 1.000 |
Disease duration (Month), mean (SD) | 108.1(83.5) | 72.8(41.6) | 0.003 | 66.6(66.2) | 88.6(71.1) | 0.916 |
SLEDAI-2 K,mean (SD) | 13.2(4.0) | 13.7(4.2) | 0.964 | 12.4(5.0) | 17.4(3.4) | 0.212 |
Initial organ damage | ||||||
 Lupus nephritis | 22(32.8) | 21(50.0) | 0.107 | 6(31.6) | 5(71.4) | 0.095 |
 Neuropsychiatric lupus | 4(6.0) | 0 | 0.158 | 3(15.9) | 0 | 0.540 |
 Lupus pneumonia | 2(3.0) | 0 | 0.522 | 1(5.3) | 0 | 1.000 |
 Lupus related cardiac damage | 0 | 1(2.4) | 0.385 | 0 | 1(14.3) | 0.269 |
 Gastrointestinal damage | 1(1.5) | 0 | 1.000 | 1(5.3) | 0 | 1.000 |
Initial treatment | ||||||
 Glucocorticoid amount (mg/kg/d), mean (SD) | 0.82(0.32) | 1.05(0.47) | < 0.001 | 1.0(0.36) | 1.31(0.24) | 0.050 |
 Glucocorticoid cumulative at the time of achieving clinical remission (mg), mean (SD) | 1653.7(942.4) | 2384.7(1390.0) | < 0.001 | 2215.7(1112.3) | 3418.0(601.9) | 0.005 |
 Hydroxychloroquine, n (%) | 54(80.6) | 38(90.5) | 0.188 | 15(78.9) | 6(85.7) | 1.000 |
 Immunosuppressors, n (%) | 30(44.8) a | 28(66.7) b | 0.031 | 9(47.4) c | 7(100.0) d | 0.023 |
 Patient’s self-discontinuation of medication maintenance therapy, n (%) | 35(15.0) | 0 | < 0.001 | 8(42.1) | 0 | 0.062 |